Step therapy

Step therapy is a PBM utilization management protocol that requires patients to try (and document failure of, intolerance to, or contraindication for) a preferred lower-cost drug before the PBM will approve coverage for a non-preferred higher-cost drug in the same therapeutic class. Step therapy operates through prior authorization rules tied to the PBM's formulary tier structure. PBM audits routinely verify step therapy compliance on dispensed claims and recoup where the step-therapy documentation is missing or inadequate.

How step therapy works

The PBM publishes step therapy rules in the formulary documentation. For a given therapeutic class (statins, GLP-1 receptor agonists, oncology, biologics, mental health), the PBM identifies a preferred Step 1 drug (often a lower-cost generic or a contracted-rebate brand) and one or more Step 2 drugs (the non-preferred higher-cost option). A prescription for Step 2 typically requires either documented trial-and-failure of Step 1 over a defined period, intolerance documentation, or a contraindication documented in the patient record.

The prescriber submits the step therapy override through the PBM's prior authorization process (ePA via CoverMyMeds, Surescripts, or PBM-direct portal). The pharmacy dispenses on the basis of the approved prior authorization. PBM audits verify that the underlying step-therapy documentation supports the override determination. Audit findings of inadequate step therapy support recoupment of the Step 2 reimbursement and, in some matters, network discipline.

When step therapy applies

Step therapy applies wherever the PBM's formulary structure includes step therapy rules. Major PBMs apply step therapy across most therapeutic classes with meaningful generic alternatives. Medicare Part D plans operate within CMS-approved formularies that may include step therapy with patient protections. State step therapy reform laws in over 30 states add procedural protections including exception processes, urgency timelines, and continuity-of-care protections for patients already stabilized on a Step 2 drug.

The pharmacy's exposure under step therapy audit findings

Per-claim recoupment on step therapy findings runs as the full Step 2 reimbursement, not the difference between Step 2 and Step 1. Statistical extrapolation can scale individual findings into substantial dollar demands across the claim universe. Network exposure runs through repeated step therapy deficiencies that can support termination for cause. The defense framework focuses on prescriber-record documentation reconstruction, prior-authorization audit trail, state step therapy reform law application, and methodology challenge where extrapolation scales the exposure.

Related terms

• Prior authorization The PBM approval process through which step therapy overrides are typically processed.
• Formulary The PBM-published drug list and tier structure that defines step therapy preference.
• PBM audit The audit framework where step therapy compliance is routinely verified.
• DAW The NCPDP code framework that operates alongside step therapy in claim adjudication.

See also

• Practice area
  PBM Audit Defense

  PBM audit defense framework including step therapy findings response.

• Practice area
  Recoupment Defense

  Defense framework for step-therapy-driven recoupment demands.